Table 3.
Rates of NR*, ETR† and SVR‡ in HCV infected patients of different Age groups to interferon plus ribavirin therapy (N = 400).
| S. No. | AGE GROUP | TOTAL PATIENTS | NR (%) | ETR (%) | SVR (%) |
|---|---|---|---|---|---|
| 1 | ≤ 20 Years | 9 | 1 (11.1%) | 8 (88.9%) | 6 (66.7%) |
| 2 | 21–30 Years | 91 | 27 (29.7%) | 64 (70.3%) | 50 (54.9%) |
| 3 | 31–40 Years | 154 | 48 (31.2%) | 106 (68.8%) | 88 (57.1%) |
| 4 | 41–50 Years | 107 | 40 (37.4%) | 67 (62.6%) | 48 (44.9%) |
| 5 | 51–60 Years | 37 | 14 (37.8%) | 23 (62.2%) | 10 (27.1%) |
| 6 | > 60 Years | 2 | 2 (100%) | 0 | 0 |
| Total | 400 | 132 (33%) | 268 (67%) | 202 (50.5%) | |
*NR, Non-responders, defined as detectable HCV RNA at the end of anti-viral treatment.
†ETR, End of treatment response, defined as undetectable HCV RNA at the end of treatment.
‡SVR-Sustained virologic response, defined as undetectable HCV RNA 24 weeks after end of anti-viral treatment.